NMR — NOMURA ETF TR

Public company

Sign in to save2 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying NMR?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
95
Institutional Conviction
Strong distribution · 0 buying vs 2 selling last quarter
4
Macro Tailwind
Macro conditions are mixed for this sector
46
Why? — Evidence & Confidence ▾

Of 2 tracked investors who changed their NMR position last quarter, 0 bought and 2 sold (0% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 46/100 in a Overheat regime).

Supporting evidence
  • +2 tracked investors reported holding NMR at their latest filing
Contradicting evidence — always shown
  • −2 tracked investors reduced or exited last quarter (0 reduced, 2 sold out)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 10/21/2026.

About NOMURA ETF TR (NMR)

NOMURA ETF TR (NMR) appears in the most recent 13F filings of 2 tracked institutional investors. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $11M. Across recent filings, tracked investors recorded 1 new positions, 0 increased, 1 reduced, and 2 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in NMR

25
/100
Institutional Distribution
Added / Increased1
Reduced1
Exited2
BearishBullish
Crowded Trade Score™

How many top investors track NMR

13
/100
Undiscovered
2investors

Only 2 tracked investors report this position.

UndiscoveredCrowded
151015+

NMR Ownership Composition

How NOMURA ETF TR is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
100% of tracked value
Institutions
2
tracked investors
Total Reported
$14.3M
combined 13F value
Types1
  • Multi-Strategy / Quant100.0%
Multi-Strategy / Quant(2)
100.0%

Tracked investors currently reporting NMR

1 tracked investor has since exited this position — listed separately below.

  • Izzy EnglanderJun 30, 2026
    Millennium Management
    Shares
    1.3M
    Value
    $11.1M
    % Portfolio
    0.00%
  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    44.5K
    Value
    $3.2M
    % Portfolio
    0.00%

Previously held NMR

These investors reported NMR in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

InvestorFirmLast reported sharesValue thenLast held
Steve CohenPoint72 Asset Management99.4K$575.5KDec 31, 2024

Recent activity

Frequently asked questions

How many institutional investors hold NMR?
2 tracked institutional investors disclosed a position in NMR (NOMURA ETF TR) in their most recent 13F filing.
Who is the largest institutional holder of NMR?
Izzy Englander, Millennium Management, holds the largest disclosed position in NMR, valued at $11M.
Did institutional ownership of NMR increase or decrease?
Across recent 13F filings, tracked investors recorded 1 new positions, 0 increased, 1 reduced, and 2 fully exited NMR.
Where does this NMR ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.